SAFETY DATA SHEET  
Terephthalic Acid (All Grades)

1. CHEMICAL PRODUCT/COMPANY IDENTIFICATION

PRODUCT IDENTIFIER:
Terephthalic Acid (All Grades)

ADDITIONAL IDENTIFICATION:
1,4-Benzenedicarboxylic Acid  PGTPA
KP–12  PTA
TPA

RECOMMENDED USE AND USE RESTRICTIONS:
A monomer used in the manufacturing of plastics. See attached DAK Caution Bulletin No. 1 at end of SDS for use restrictions.

MANUFACTURER / SUPPLIER:
DAK Americas LLC
5925 Carnegie Blvd., Suite 500
Charlotte, NC 28209
www.DAKAmericas.com

EMERGENCY PHONE NUMBERS:
Product Information: 1–800–237–8275
Transport Emergency: CHEMTREC 1–800–424–9300

2. HAZARDS IDENTIFICATION

OSHA HAZARD CLASSIFICATION:
COMBUSTIBLE DUST - WARNING! MAY FORM COMBUSTIBLE DUST CONCENTRATIONS IN AIR.

3. COMPOSITION/INFORMATION ON INGREDIENTS

COMPONENTS:
Material | CAS Number | %
--- | --- | ---
Terephthalic Acid | 100–21–0 | >99.8
Acetic Acid | 64–19–7 | 0.15

4. FIRST AID MEASURES

DESCRIPTION OF NECESSARY MEASURES:

INHALATION: If large amounts are inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Call a physician.

SKIN CONTACT: Flush skin with water after excessive contact. Wash contaminated clothing before reuse.

EYE CONTACT: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Consult a physician.

INGESTION: If swallowed, immediately give 2 glasses of water and induce vomiting. Never give anything by mouth to an unconscious person. Call a physician.

MOST IMPORTANT SYMPTOMS/EFFECTS, ACUTE AND DELAYED:
None expected during normal industrial or commercial handling.

INDICATION OF IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT:
None expected during normal industrial or commercial handling.
5. **FIRE FIGHTING MEASURES**

**SUITABLE EXTINGUISHING MEDIA:**
Water, Water Spray, Foam, Carbon Dioxide (CO₂), or Dry Chemical.

**SPECIFIC HAZARDS ARISING FROM CHEMICAL:**
HAZARDOUS COMBUSTION PRODUCTS: Carbon dioxide and carbon monoxide.

**SPECIAL PROTECTIVE EQUIPMENT AND PRECAUTIONS FOR FIRE-FIGHTERS:**
Keep personnel removed and upwind of fire. Wear self-contained breathing apparatus. Wear full protective equipment. Dust forms explosive mixture with air. High-voltage static electricity buildup is possible when significant quantities of dust are present in the air. This can be a potential source of ignition.

6. **ACCIDENTAL RELEASE MEASURES**

**PERSONAL PRECAUTIONS / PROTECTIVE EQUIPMENT / EMERGENCY PROCEDURES**
Review Section 5. FIRE FIGHTING MEASURES and Section 7. PRECAUTIONS FOR SAFE HANDLING before proceeding with clean-up. Use appropriate Personal Protective Equipment during clean-up.

**METHODS AND MATERIALS FOR CONTAINMENT AND CLEANING UP:**
Remove source of heat, sparks, flame, impact, friction or electricity. Recover undamaged and minimally contaminated material for reuse and reclamation.

Dust Deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Non-sparking tools should be used.

7. **HANDLING AND STORAGE**

**PRECAUTIONS FOR SAFE HANDLING:**
- Avoid breathing dust and avoid contact with eyes, skin, or clothing.
- Vapor space above TPA may contain acetic acid in concentrations above its exposure limits.
- Wash thoroughly after handling.
- Keep away from heat, sparks and flames.
- Close container after each use.
- Avoid dust generation and prevent dust accumulations to minimize explosion hazard. Physical operations, such as grinding, can create dust and a potential dust explosion hazard. Under these conditions, follow National Fire Protection Association (NFPA) Codes and Standards for handling combustible dusts.

**CONDITIONS FOR SAFE STORAGE, INCLUDING ANY INCOMPATIBILITIES:**
Do not mix with strong oxidants. Store in a well-ventilated place. Keep container tightly closed.
## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### EXPOSURE LIMITS:

<table>
<thead>
<tr>
<th></th>
<th>Acetic Acid</th>
<th>Terephthalic Acid</th>
<th>Particulates Not Otherwise Regulated (PNOR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEL (OSHA):</td>
<td>10 ppm</td>
<td>-</td>
<td>15 mg/m³ Total dust</td>
</tr>
<tr>
<td>TLV (ACGIH):</td>
<td>10 ppm (STEL)</td>
<td>10 mg/m³</td>
<td>5 mg/m³ Respirable fraction</td>
</tr>
</tbody>
</table>

*All exposure limits presented are 8-hour time weighted average (TWA) limits unless otherwise noted.*

### APPROPRIATE ENGINEERING CONTROLS:

- Keep container tightly closed.
- Use sufficient ventilation to keep employee exposure below recommended exposure limits.
- Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).
- Use static controls. Static charges can build up and ignite dust or solvent laden atmospheres. Design precautions into processes that can create dust, such as pneumatic conveying systems, grinding and other physical operations. There is the potential for a dust explosion hazard.

### INDIVIDUAL PROTECTION MEASURES / PERSONAL PROTECTIVE EQUIPMENT:

#### EYE/FACE PROTECTION:
Wear safety glasses. Wear coverall chemical splash goggles and face shield when the possibility exists for eye or face contact from airborne material.

#### RESPIRATORY PROTECTION:
Where airborne concentrations are expected to exceed exposure limits, a NIOSH approved respirator should be selected based on the form and concentration of the contaminant in air and in accordance with the OSHA Respiratory Protection Standard (29 CFR 1910.134).

#### PROTECTIVE CLOTHING:
Wear impervious clothing, such as gloves, apron, boots, or whole bodysuit made from butyl rubber, as appropriate.

### RECOMMENDED DECONTAMINATION FACILITIES:
Eyewash station, washing facilities.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

- **Appearance:** White, powder
- **Odor:** Vinegar
- **Odor Threshold:** No data available
- **pH:** Not Applicable
- **Melting Point:** >300 °C
- **Initial Boiling Point and Boiling Range:** Sublimes above 300 °C
- **Flash Point:** 260 °C; Method – OC
- **Evaporation Rate:** No data available
- **Flammability:** No data available
- **Flammability Limits (Upper/Lower):** No data available
- **Vapor Pressure:** <0.01 mm Hg @ 20 °C
- **Vapor Density:** No data available
- **Specific Gravity:** 1.51
- **Solubility in Water:** Negligible
- **Partition coefficient (n-octanol/water):** No data available
- **Auto-Ignition Temperature:** No data available
- **Decomposition Temperature:** 300 °C
- **Viscosity:** No data available
10. STABILITY AND REACTIVITY

REACTIVITY:
None known.

CHEMICAL STABILITY:
Stable at normal conditions. Polymerization will not occur.

POSSIBILITY OF HAZARDOUS REACTIONS:
None known.

CONDITIONS TO AVOID:
Temperatures above 300 °C. Decomposes with heat.

INCOMPATIBLE MATERIALS:
Incompatible with strong oxidants.

HAZARDOUS DECOMPOSITION PRODUCTS:
Not known.

11. TOXICOLOGICAL INFORMATION

INFORMATION ON LIKELY ROUTES OF EXPOSURE:
Dust may be inhaled, and come in contact with skin and eyes.

SYMPTOMS RELATED TO PHYSICAL, CHEMICAL AND TOXICOLOGICAL CHARACTERISTICS:
- Eye contact may cause slight irritation, with discomfort, tearing, or blurring of vision.
- Inhalation may cause irritation of mucosal surfaces.

ACUTE, DELAYED, AND CHRONIC EFFECTS FROM SHORT AND LONG-TERM EXPOSURE:
- High or prolonged oral exposure may result in kidney changes, blood in the urine or bladder stones.
- Based on animal studies, high or prolonged oral exposure may result in kidney changes, blood in the urine or bladder stones.
- The compound is a slight eye irritant, but is neither a skin irritant nor a skin sensitizer in animals.
- Toxic effects described in animals from exposure by ingestion include bladder hemorrhage and stomach ulceration. Toxicity described for repeated doses include bladder calculi (stones), blood in the urine, and decreased weight gain.
- Animal testing indicates that this compound does not have reproductive effects. Limited information from reproduction studies does not indicate that terephthalic acid is a unique hazard to the conceptus.
- Toxicity described in animals administered the compound orally in the diet include bladder stones and alterations of the urinary tract with tumors and squamous cell carcinomas, decreased growth rate and altered relative organ weights.

NUMERICAL MEASURES OF TOXICITY
- Oral LD<sub>50</sub>: 18,800 mg/kg in rats
- Terephthalic acid is a carcinogen in rats when administered in large oral doses (>1,000 mg/kg/day). The compound does not produce genetic damage in bacterial cell cultures.

CARCINOGENICITY INFORMATION:
None of the components present in this material at concentrations equal to or greater than 0.1% are listed by IARC, NTP, OSHA or ACGIH as a carcinogen.
12. ECOLOGICAL INFORMATION
No toxicity data is available.

13. DISPOSAL CONSIDERATIONS
Treatment, storage, transportation and disposal must be in accordance with applicable Federal, State, and local regulations. Recover non–usable free liquid and dispose of in an approved and permitted incinerator. Recover contaminated liquid and dispose of in an approved and permitted biological treatment system. Remove non–usable solid material and/or contaminated soil, for disposal in an approved and permitted landfill.

14. TRANSPORTATION INFORMATION

SHIPPING INFORMATION:
Shipping Containers
   Tank Cars: 190,000 lbs. net
   Tank Trucks: 50,000 lbs. net

Terephthalic acid is not regulated as a hazardous material by DOT, IMO or IATA.

15. REGULATORY INFORMATION

U.S. FEDERAL REGULATIONS:
   ➢ TSCA Inventory Status: Reported/Included.
   ➢ Title III Hazard Classification Sections 311, 312
     – Acute: Yes  – Reactivity: No
     – Chronic: Yes  – Pressure: No
     – Fire: No
   ➢ Lists
     – SARA Extremely Hazardous Substance: No
     – CERCLA Hazardous Material: No
     – SARA Toxic Chemical: No

16. ADDITIONAL INFORMATION
The data in this Safety Data Sheet relates only to the specific material designated herein and does not relate to use in combination with any other material or in any process.

SDS Revision Date: April 20, 2015

End of SDS
DAK CAUTION BULLETIN NO.1

DO NOT USE DAK MATERIALS IN MEDICAL APPLICATIONS INVOLVING PERMANENT, BRIEF, OR TEMPORARY IMPLANTATION IN THE HUMAN BODY OR PERMANENT CONTACT WITH INTERNAL BODY FLUIDS OR TISSUES, UNLESS THE MATERIAL HAS BEEN PROVIDED DIRECTLY FROM DAK UNDER A CONTRACT WHICH EXPRESSLY ACKNOWLEDGES THE CONTEMPLATED USE.

DAK MAKES NO REPRESENTATION, PROMISE, EXPRESS WARRANTY OR IMPLIED WARRANTY CONCERNING THE SUITABILITY OF THESE MATERIALS FOR USE IN THE HUMAN BODY OR IN CONTACT WITH INTERNAL BODY FLUIDS OR TISSUES.

THE CONTENT OF DAK MATERIAL IS NOT CERTIFIED FOR IMPLANTS.
DAK materials are not designed or manufactured for use in implantation in the human body or in contact with internal body fluids or tissues. DAK has not performed clinical testing of these materials for implantation. DAK will not provide to customers making implantable devices any notice concerning its materials, as specified under 21 CFR section 820.50, or any other information necessary for medical device use of the materials under any other statute or FDA regulation. DAK has neither sought, nor received, approval from the FDA for the use of these materials in implantation in the human body or in contact with internal body fluids or tissues.

ALL IMPLANTABLE MEDICAL DEVICES CARRY A RISK OF FAILURE AND ADVERSE CONSEQUENCES
The medical judgment of a physician, a medical device seller and the FDA should be relied upon for identification of both harmful consequences and life-saving benefits from an implantation device comprised of specific materials. These benefits and risks can be found in published medical cases performing clinical medical studies of an implantable medical device. DAK does not support the use of its products in these applications and cannot weigh the benefits against the risk defined in these articles. DAK can not offer a medical judgment on the safety or efficacy of the use of its materials in such devices.

DO NOT MAKE REFERENCE TO THE DAK NAME OR ANY DAK TRADEMARK IN ASSOCIATION WITH AN IMPLANTABLE MEDICAL DEVICE.
Do not use a DAK trademark or licensed trademark as the descriptive name of an implantable medical device (e.g. do not call it the "Delcron®" prosthesis, or do not call it a "Laser+® device").

End of Bulletin